Kardos P, Lehrl S, Kamin W, Matthys H
Group Practice and Centre for Pneumology, Allergy and Sleep Medicine at Red Cross Maingau Hospital, Frankfurt am Main.
Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen.
Pneumologie. 2014 Aug;68(8):542-6. doi: 10.1055/s-0034-1377332. Epub 2014 Jul 8.
Acute bronchitis (AB) is a highly contagious infection of the airways, presenting mostly in connection with common cold (CC). There is a high variance in duration and course of symptoms which, sooner or later, also may disappear spontaneously and change during the course of the disease. Therefore, assessment of treatment outcome is difficult.
Composite outcome measures are commonly used to examine the effects of pharmacotherapy in complex diseases. We discuss the features of the Bronchitis Severity Scale (BSS) on the basis of the available literature.
For the BSS the five most important symptoms of AB are rated by the patient and the physician. Since its introduction in 1996, the BSS has been used in many clinical trials evaluating treatment effects of AB. Its score correlates well with clinical findings. As thorough validation analyses revealed, this applies even more to the BSS subscales "cough domain" and "sputum domain".
The validated BSS appears to be a reliable tool to assess therapeutic effects in CC/AB. The BSS and its subscales are recommended as outcome measures for future drug trials in CC/AB, but also help physicians to focus their consultation in patients with CC/AB.
急性支气管炎（AB）是一种具有高度传染性的气道感染，大多与普通感冒（CC）相关。症状的持续时间和病程差异很大，迟早可能会自行消失，且在疾病过程中会发生变化。因此，评估治疗效果很困难。
复合结局指标常用于检验药物治疗在复杂疾病中的效果。我们根据现有文献讨论支气管炎严重程度量表（BSS）的特点。
对于BSS，患者和医生对AB的五个最重要症状进行评分。自1996年推出以来，BSS已在许多评估AB治疗效果的临床试验中使用。其评分与临床发现密切相关。正如全面的验证分析所揭示的，这在BSS子量表“咳嗽领域”和“痰液领域”中表现得更为明显。
经过验证的BSS似乎是评估CC/AB治疗效果的可靠工具。BSS及其子量表被推荐作为未来CC/AB药物试验的结局指标，同时也有助于医生在CC/AB患者的咨询中重点关注。
